Lucero Bio - Innovative work with 3D cell models stage 2
| Reference number | |
| Coordinator | Lucero AB |
| Funding from Vinnova | SEK 900 000 |
| Project duration | May 2022 - January 2023 |
| Status | Completed |
| Venture | Innovative Startups |
| Call | Innovative Startups step 2 spring 2022 |
Important results from the project
Through this project, Lucero significantly de-risked our technology and began working towards a fully automated system. We were also able to demonstrate our AI in real-time. These two technical milestones are key evidence that we will use to set up a pilot project with a pharmaceutical partner.
Expected long term effects
The positive results of this project, in addition to our finalized phototox data, mean that we can move forward with a more complex pilot project in the new year. We demonstrated the functionality of our AI in real-time, created a functional GUI, and have shown a full isolation protocol. These milestones were requirements from our customers before they would consider a pilot project with us. The results also allowed us to secure funding from the EIC for the next three years.
Approach and implementation
Overall, the project was a success. We significantly de-risked our system and we have established partnerships to enable us to continue to do so after the completion of this project. We did face challenges regarding the sourcing of primary biological material. However, we are confident that with the new resources we will receive in 2023, we will be able to stick to our business plan and development timeline.